Sanofi (FRA:SNW)
Germany · Delayed Price · Currency is EUR | Market Cap | 96.04B |
| Revenue (ttm) | 45.74B |
| Net Income (ttm) | 9.13B |
| Shares Out | n/a |
| EPS (ttm) | 7.35 |
| PE Ratio | 10.52 |
| Forward PE | 9.40 |
| Dividend | 3.92 (4.57%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 2,735 |
| Average Volume | 10,011 |
| Open | 77.97 |
| Previous Close | 79.19 |
| Day's Range | 77.85 - 78.75 |
| 52-Week Range | 78.41 - 110.82 |
| Beta | n/a |
| RSI | 29.89 |
| Earnings Date | Jul 31, 2025 |
About R1 RCM
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Sanofi (SNY) Q2 2025 Earnings Call Transcript
Sanofi (NASDAQ:SNY) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsBrian Foard - Executive VP & Head of Specialty...
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
Press release: Online availability of Sanofi's half-year financial report for 2025
Online availability of Sanofi's half-year financial report for 2025 Paris, July 31, 2025 . Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and...
Press release: Online availability of Sanofi's half-year financial report for 2025
Online availability of Sanofi's half-year financial report for 2025 Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and ...
Sanofi 2025 Q2 - Results - Earnings Call Presentation
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
Sanofi SA (NASDAQ: SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion . Sales increased 6% year over year, up 10.1% in consta...
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
Sanofi SA SNY reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.
Sanofi CEO Paul Hudson on Q2 results, Dupixent demand and tariff impact
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong demand for Dupixent, drug pipeline outlook, impact of tariffs, and more.
Sanofi CEO Paul Hudson on Q2 results, Dupixent demand and tariff impact
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong demand for Dupixent, drug pipeline outlook, impact of tariffs, and more.
Sanofi revises annual sales growth expectations on strong Dupixent demand
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer tr...
Sanofi gives Q2 results
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range.
Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment...
U.S. and European Union trade deal could cost the pharma industry up to $19 billion
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Daniel...
Sanofi (SNY) to Acquire Vicebio in Strategic Expansion
Sanofi (SNY) to Acquire Vicebio in Strategic Expansion
Key deals this week: Sanofi, SentinelOne, Marex Group, Synovus Financial, Union Pacific and more
Sanofi gets EU nod for Sarclisa combination in multiple myeloma
Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction t...
Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma